Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018700 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
A Phase 3 study of Episodic Migraine, sponsored by Merz Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 990
- Enrollment target
- 20
- Study locations
NCT07018700 is a Phase 3 study of Episodic Migraine that is actively recruiting participants, run by Merz Therapeutics. The registered enrollment target is 990 participants, above the 420-participant average among 13 other Episodic Migraine trials with a reported enrollment target (136% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT07018700, a Phase 3 study of Episodic Migraine, is actively recruiting participants, sponsored by Merz Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 990 participants
- Enrollment target
- 20
- Study locations
Study Summary
In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Xeomin
Study Locations (20)
Florida
- Northwest Florida Clinical Research Group, Merz Investigational Site #0010286 - Gulf Breeze
- Nexus Clinical Research Center, Merz Investigational Site #0010514 - Homestead
- Jacksonville Center for Clinical Research, Merz Investigational Site #0010515 - Jacksonville
- Clinical Research of Central Florida, Merz Investigational Site #0010532 - Lakeland
- American Research Institute, Merz Investigational Site #0010492 - Miami
- Premiere Research Institute at Palm Beach Neurology, Merz Investigational Site #0010499 - West Palm Beach
California
- Chemidox Clinical Trials Inc, Merz Investigational Site #0010488 - Lancaster
- Clinical Research Institute, Merz Investigational Site #0010487 - Los Angeles
- Clinical Trials Management Services, Merz Investigational Site #0010526 - Thousand Oaks
- BNL Health Inc., Merz Investigational Site #0010489 - Torrance
Connecticut
- Hasbani Neurology, Merz Investigational Site #0010509 - New Haven
- Yale Center for Clinical Investigations, Merz Investigational Site #0010527 - New Haven
- New England Institute Neurology and Headache, Merz Investigational Site #0010441 - Stamford
Arizona
- TrialSphere Corp, Merz Investigational Site #0010513 - Chandler
- Arizona Neuroscience Research, Merz Investigational Site #0010521 - Phoenix
Arkansas
- Baptist Health Medical Center, Merz Investigational Site #0010520 - Little Rock
Georgia
- Accel Research - NeuroStudies, Merz Investigational Site #0010523 - Decatur
Hawaii
- Hawaii Pacific Neuroscience, Merz Investigational Site #0010510 - Honolulu
Kansas
- Kansas Institute of Research,, Merz Investigational Site #0010495 - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 990 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07018700
The ClinicalTrials.gov registry entry for NCT07018700 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 990 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 420-participant average among 13 other Episodic Migraine trials with a reported enrollment target (136% higher). The listed sponsor is Merz Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07018700 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07018700 about?
NCT07018700 is a clinical study titled "A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine". In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration...
What is the current status of trial NCT07018700?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 990 participants. The study started on 2025-08-21. Estimated completion is 2027-10.
What conditions does trial NCT07018700 study?
This clinical trial studies the following conditions: Episodic Migraine.
What interventions are being tested in trial NCT07018700?
The interventions under investigation include: Placebo (DRUG), Xeomin (DRUG).
Who is sponsoring clinical trial NCT07018700?
This trial is sponsored by Merz Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07018700 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Episodic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
RECRUITING · Phase 3
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
ACTIVE NOT RECRUITING · Phase 3
-
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
COMPLETED · Phase 3
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.